Hypermarcas (OTCMKTS:HYPMY) Short Interest Update

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,225 shares, a decline of 32.9% from the August 15th total of 9,271 shares. Based on an average trading volume of 7,201 shares, the short-interest ratio is presently 0.9 days. Currently, 0.0% of the company’s shares are sold short.

Hypermarcas Price Performance

Shares of HYPMY opened at $4.50 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. Hypermarcas has a 1 year low of $3.71 and a 1 year high of $5.50. The stock has a market cap of $3.17 billion, a P/E ratio of 9.01 and a beta of 0.71. The stock’s 50-day moving average price is $4.21 and its two-hundred day moving average price is $4.30.

Hypermarcas (OTCMKTS:HYPMY) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, equities analysts predict that Hypermarcas will post 0.53 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.